Concepts (156)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glaucoma | 10 | 2026 | 73 | 3.490 |
Why?
|
| Tomography, Optical Coherence | 11 | 2026 | 439 | 2.270 |
Why?
|
| Glaucoma, Angle-Closure | 7 | 2020 | 13 | 1.930 |
Why?
|
| Intraocular Pressure | 19 | 2025 | 107 | 1.830 |
Why?
|
| Glaucoma Drainage Implants | 5 | 2023 | 9 | 1.790 |
Why?
|
| Anterior Eye Segment | 8 | 2020 | 24 | 1.780 |
Why?
|
| Iris | 6 | 2017 | 36 | 1.770 |
Why?
|
| Laser Coagulation | 4 | 2022 | 113 | 0.730 |
Why?
|
| Ocular Hypotension | 2 | 2023 | 4 | 0.690 |
Why?
|
| Ciliary Body | 3 | 2022 | 18 | 0.680 |
Why?
|
| Glaucoma, Open-Angle | 5 | 2018 | 26 | 0.610 |
Why?
|
| Gonioscopy | 7 | 2020 | 8 | 0.610 |
Why?
|
| Trabecular Meshwork | 5 | 2018 | 11 | 0.600 |
Why?
|
| Sturge-Weber Syndrome | 3 | 2025 | 9 | 0.590 |
Why?
|
| Ophthalmologic Surgical Procedures | 2 | 2016 | 91 | 0.540 |
Why?
|
| Iridectomy | 2 | 2020 | 3 | 0.530 |
Why?
|
| Eye Injuries, Penetrating | 1 | 2017 | 16 | 0.530 |
Why?
|
| Visual Acuity | 5 | 2018 | 516 | 0.500 |
Why?
|
| Lasers | 1 | 2016 | 111 | 0.470 |
Why?
|
| Eye Injuries | 1 | 2016 | 50 | 0.460 |
Why?
|
| Cataract Extraction | 1 | 2016 | 127 | 0.450 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2016 | 215 | 0.420 |
Why?
|
| Tonometry, Ocular | 5 | 2018 | 22 | 0.350 |
Why?
|
| Herpesvirus 2, Human | 1 | 2011 | 16 | 0.340 |
Why?
|
| Eye Infections, Viral | 1 | 2011 | 24 | 0.340 |
Why?
|
| Herpesvirus 1, Human | 1 | 2011 | 40 | 0.330 |
Why?
|
| Herpes Simplex | 1 | 2011 | 59 | 0.330 |
Why?
|
| Eyelid Diseases | 1 | 2011 | 58 | 0.320 |
Why?
|
| Ocular Hypertension | 2 | 2023 | 17 | 0.310 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2057 | 0.300 |
Why?
|
| Iris Diseases | 2 | 2020 | 11 | 0.300 |
Why?
|
| Humans | 33 | 2026 | 130075 | 0.250 |
Why?
|
| Anterior Chamber | 2 | 2017 | 26 | 0.250 |
Why?
|
| Port-Wine Stain | 2 | 2022 | 10 | 0.230 |
Why?
|
| Middle Aged | 15 | 2020 | 28315 | 0.230 |
Why?
|
| Phospholipase C gamma | 1 | 2025 | 27 | 0.230 |
Why?
|
| Vision, Ocular | 1 | 2025 | 117 | 0.210 |
Why?
|
| Delphi Technique | 1 | 2025 | 277 | 0.210 |
Why?
|
| Aged | 13 | 2023 | 20822 | 0.190 |
Why?
|
| Retrospective Studies | 10 | 2023 | 17538 | 0.190 |
Why?
|
| Consensus | 2 | 2025 | 521 | 0.190 |
Why?
|
| Disease Management | 1 | 2025 | 554 | 0.180 |
Why?
|
| Aniridia | 1 | 2021 | 11 | 0.170 |
Why?
|
| Ophthalmology | 2 | 2021 | 175 | 0.170 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 1 | 2021 | 27 | 0.170 |
Why?
|
| Male | 17 | 2025 | 64382 | 0.170 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 2021 | 41 | 0.170 |
Why?
|
| Coloboma | 1 | 2021 | 40 | 0.170 |
Why?
|
| Microscopy, Acoustic | 2 | 2020 | 15 | 0.170 |
Why?
|
| Female | 17 | 2025 | 70240 | 0.170 |
Why?
|
| Pupil Disorders | 1 | 2020 | 18 | 0.160 |
Why?
|
| Cerebellar Ataxia | 1 | 2021 | 61 | 0.160 |
Why?
|
| Introns | 1 | 2021 | 279 | 0.160 |
Why?
|
| Optic Nerve Diseases | 1 | 2021 | 76 | 0.150 |
Why?
|
| Trabeculectomy | 2 | 2025 | 11 | 0.150 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2018 | 2825 | 0.150 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2018 | 21 | 0.140 |
Why?
|
| Anatomic Landmarks | 1 | 2018 | 20 | 0.140 |
Why?
|
| Limbus Corneae | 1 | 2018 | 31 | 0.140 |
Why?
|
| Equipment Failure | 1 | 2018 | 122 | 0.140 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2020 | 180 | 0.130 |
Why?
|
| Ophthalmologists | 1 | 2017 | 10 | 0.130 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 820 | 0.130 |
Why?
|
| Radiologists | 1 | 2017 | 52 | 0.130 |
Why?
|
| Bevacizumab | 1 | 2017 | 56 | 0.130 |
Why?
|
| Lasers, Solid-State | 1 | 2017 | 23 | 0.130 |
Why?
|
| Drainage | 1 | 2018 | 246 | 0.130 |
Why?
|
| Prosthesis Failure | 1 | 2017 | 160 | 0.120 |
Why?
|
| Eye Abnormalities | 1 | 2017 | 104 | 0.120 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2017 | 105 | 0.120 |
Why?
|
| Students, Medical | 1 | 2020 | 346 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 1 | 2017 | 227 | 0.120 |
Why?
|
| Demography | 1 | 2016 | 236 | 0.120 |
Why?
|
| Phacoemulsification | 2 | 2017 | 131 | 0.110 |
Why?
|
| Young Adult | 4 | 2017 | 9979 | 0.110 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 2076 | 0.110 |
Why?
|
| Adult | 8 | 2025 | 31012 | 0.110 |
Why?
|
| Laser Therapy | 1 | 2017 | 241 | 0.110 |
Why?
|
| Adolescent | 5 | 2017 | 20796 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 1282 | 0.100 |
Why?
|
| Telemedicine | 1 | 2020 | 525 | 0.100 |
Why?
|
| Intellectual Disability | 1 | 2021 | 1088 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1112 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2021 | 3407 | 0.090 |
Why?
|
| ROC Curve | 3 | 2020 | 609 | 0.090 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 1212 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 2891 | 0.090 |
Why?
|
| Acyclovir | 1 | 2011 | 49 | 0.090 |
Why?
|
| Valine | 1 | 2011 | 110 | 0.080 |
Why?
|
| Internship and Residency | 1 | 2020 | 1217 | 0.080 |
Why?
|
| Child | 4 | 2025 | 26168 | 0.080 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2011 | 211 | 0.070 |
Why?
|
| Neuroimaging | 2 | 2021 | 381 | 0.070 |
Why?
|
| Mutation | 1 | 2021 | 6067 | 0.060 |
Why?
|
| Recurrence | 1 | 2011 | 1475 | 0.060 |
Why?
|
| Aging | 1 | 2013 | 1238 | 0.060 |
Why?
|
| Antiviral Agents | 1 | 2011 | 802 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2017 | 3114 | 0.060 |
Why?
|
| Prospective Studies | 1 | 2016 | 6401 | 0.060 |
Why?
|
| Bimatoprost | 1 | 2023 | 1 | 0.050 |
Why?
|
| Cloprostenol | 1 | 2023 | 1 | 0.050 |
Why?
|
| Amides | 1 | 2023 | 81 | 0.050 |
Why?
|
| Ophthalmic Solutions | 1 | 2023 | 86 | 0.050 |
Why?
|
| Heterozygote | 1 | 2025 | 722 | 0.050 |
Why?
|
| Genotype | 2 | 2018 | 2588 | 0.050 |
Why?
|
| Eye | 1 | 2023 | 215 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2018 | 3349 | 0.040 |
Why?
|
| Retinal Vessels | 1 | 2021 | 48 | 0.040 |
Why?
|
| Ambulatory Care Facilities | 1 | 2023 | 231 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2022 | 5166 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2025 | 920 | 0.040 |
Why?
|
| Facies | 1 | 2021 | 157 | 0.040 |
Why?
|
| Genome-Wide Association Study | 2 | 2018 | 1827 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2021 | 108 | 0.040 |
Why?
|
| Drosophila melanogaster | 1 | 2025 | 784 | 0.040 |
Why?
|
| Antihypertensive Agents | 1 | 2023 | 414 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2021 | 183 | 0.040 |
Why?
|
| Optic Nerve | 1 | 2021 | 110 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2021 | 249 | 0.040 |
Why?
|
| Phenotype | 2 | 2021 | 4456 | 0.040 |
Why?
|
| Medicare | 1 | 2023 | 442 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 3782 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 777 | 0.040 |
Why?
|
| Neurology | 1 | 2021 | 117 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 360 | 0.040 |
Why?
|
| Body Constitution | 1 | 2018 | 42 | 0.030 |
Why?
|
| Lasers, Semiconductor | 1 | 2017 | 8 | 0.030 |
Why?
|
| Argon Plasma Coagulation | 1 | 2017 | 3 | 0.030 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2017 | 27 | 0.030 |
Why?
|
| Gene-Environment Interaction | 1 | 2018 | 127 | 0.030 |
Why?
|
| Intravitreal Injections | 1 | 2017 | 35 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2018 | 730 | 0.030 |
Why?
|
| Visual Fields | 1 | 2018 | 133 | 0.030 |
Why?
|
| Alleles | 1 | 2021 | 1674 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 6765 | 0.030 |
Why?
|
| Lens Implantation, Intraocular | 1 | 2017 | 183 | 0.030 |
Why?
|
| Seizures | 1 | 2021 | 874 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 303 | 0.030 |
Why?
|
| Infant | 2 | 2021 | 13265 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 4035 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2017 | 324 | 0.030 |
Why?
|
| Curriculum | 1 | 2020 | 792 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2021 | 15002 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 674 | 0.030 |
Why?
|
| Reoperation | 1 | 2017 | 813 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2022 | 12819 | 0.030 |
Why?
|
| Research Design | 1 | 2018 | 711 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2022 | 3677 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 1874 | 0.020 |
Why?
|
| Brain | 1 | 2022 | 3146 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 3740 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 2822 | 0.020 |
Why?
|
| Software | 1 | 2013 | 733 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2021 | 8546 | 0.020 |
Why?
|
| United States | 1 | 2023 | 11893 | 0.020 |
Why?
|
| Animals | 1 | 2025 | 33660 | 0.010 |
Why?
|